FDA records identify Suzhou MicroPort OrthoRecon Co., Ltd. as the applicant behind two 510(k) clearances for total knee systems in 2026. Both submissions fall under product code JWH, regulation number 888.3560, and the orthopedic advisory committee, and both were reviewed as traditional submissions without third-party review. The filings give a dated view of the applicant's knee reconstruction line as it appears in FDA's premarket database, separate from any corporate parent or brand relationship. [1][2][3]

Two 2026 knee system clearances

K263065 covers the MicroPort Total Knee System. The submission was received on 1 September 2026 and decided on 29 October 2026 as substantially equivalent, with a summary statement included and no expedited review flag recorded. K262293 covers the EVOLUTION MPX™ Total Knee System, received 7 July 2026 and decided 10 September 2026, also substantially equivalent with a summary statement. Both list Hongxing Qiu as contact and a Suzhou, Jiangsu address on the filing. [1][2]

The FDA premarket notification page for K263065 repeats the 1 September 2026 receipt and 29 October 2026 decision, records the orthopedic review panel, and confirms the submission was traditional, not reviewed by a third party, not a combination product, and without an authorized predetermined change control plan. [3]

Device classification and components

Both clearances sit in the JWH classification: prosthesis, knee, patellofemorotibial, semi-constrained, cemented, polymer/metal/polymer, a Class 2 device under 21 CFR 888.3560. The classification describes a cemented knee replacement construct rather than a single implant, and the openFDA fields for each record carry that device name alongside the trade name. [1][2]

A separate FDA clearance, K244039 for the MedalOne Total Knee System, names the same applicant and describes a total knee replacement system composed of four component types: a femoral component, a CS tibial insert, a tibial base and a patella component. That letter, dated 28 February 2025, places the device under the same regulation number and class. [8][9][10]

Applicant identity and corporate context

The applicant name appears in FDA records as Suzhou Microport Orthorecon Co., Ltd., with a Suzhou Industrial Park address used for correspondence. An establishment registration entry lists SUZHOU MICROPORT ORTHORECON as a registered establishment. The filing address is a regulatory contact point and does not establish a headquarters location. [1][4][10]

MicroPort Scientific's 2024 annual report lists Suzhou MicroPort OrthoRecon Co., Ltd. (蘇州微創關節醫療科技有限公司) among group companies, with registered capital of RMB20,000,000 and principal activities described as manufacture, distribution, research and development of orthopedic devices. That report is the source for the ownership and activity description; FDA filings do not state a parent relationship. [6]

Scope of the documented record

The supplied collection contains two linked 510(k) records, both decided substantially equivalent, and no recall records. Those counts describe this as-of snapshot of filings only; they are not measures of total company sales, total portfolio breadth or safety performance. The record sample is the two clearances cited above, and the collection totals match that sample. [1][2]

MicroPort Orthopedics publishes an instructions-for-use document library on its own website, and that page states its products and claims apply only in the United States. The page does not identify which systems are covered by the two 2026 clearances, so commercial availability and market status of the MicroPort Total Knee System and EVOLUTION MPX™ Total Knee System remain unknown from the public documents. [5]